Yüklüyor......
Controversies in the Adjuvant Therapy of High-Grade Gliomas
The 2-year survival rate of patients with glioblastoma accrued to research studies increased from 10% to nearly 40% from 2000 to 2010. These improvements began with the demonstration of a survival benefit when daily temozolomide was administered with 6 weeks of standard radiation and for 6 months th...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
AlphaMed Press
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3228107/ https://ncbi.nlm.nih.gov/pubmed/21339260 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0335 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|